Press Releases

All Releases
View Summary NCCN Updates Guidelines for Hereditary Colon Cancer Testing
Mar 4, 2014
PDF 19.6 KB Add to Briefcase
View Summary Myriad Publishes Clinical Utility Study for Prolaris(R)
Mar 3, 2014
PDF 20.2 KB Add to Briefcase
View Summary Myriad Genetics Publishes Prolaris(R) Data in the Journal of Urology
Feb 18, 2014
PDF 17.0 KB Add to Briefcase
View Summary BRCA Patent Owners and Gene by Gene, Ltd. Resolve Patent Suit
Feb 7, 2014
PDF 17.0 KB Add to Briefcase
View Summary Myriad Genetics Reports Financial Results for Second Quarter of Fiscal Year 2014
Feb 4, 2014
PDF 27.9 KB Add to Briefcase
View Summary Myriad Genetics to Acquire Crescendo Bioscience®
Feb 4, 2014
PDF 21.4 KB Add to Briefcase
View Summary Myriad's Prolaris(R) Test Significantly Modifies Treatment Decisions for Patients With Prostate Cancer
Jan 29, 2014
PDF 16.9 KB Add to Briefcase
View Summary Myriad Publishes Data on Its Variant Classification Program in Clinical Genetics
Jan 28, 2014
PDF 15.9 KB Add to Briefcase
View Summary Myriad Genetics to Announce Financial Results for the Second Quarter of Fiscal Year 2014 on Tuesday February 4, 2014
Jan 23, 2014
PDF 12.6 KB Add to Briefcase
View Summary Myriad Genetics to Present Five Clinical Studies at 2014 ASCO GU Cancer Symposium
Jan 23, 2014
PDF 17.3 KB Add to Briefcase
View Summary Myriad Genetics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Jan 7, 2014
PDF 11.8 KB Add to Briefcase
View Summary Myriad's HRD(TM) Test Significantly Predicts Response to Cisplatin Treatment in Patients With Triple Negative Breast Cancer in Second Research Study
Dec 14, 2013
PDF 63.2 KB Add to Briefcase
View Summary Myriad myRisk Hereditary Cancer(TM) Test Significantly Improves Detection of Women at Risk for Hereditary Cancer by 51 Percent
Dec 12, 2013
PDF 17.5 KB Add to Briefcase
View Summary Myriad Genetics Announces Cancer Research Collaboration With Janssen
Dec 9, 2013
PDF 15.2 KB Add to Briefcase
View Summary Myriad Genetics Announces Upcoming Investor Event
Dec 5, 2013
PDF 12.3 KB Add to Briefcase
View Summary Myriad's Prolaris(R) Test Guides Treatment Decisions for Men with Prostate Cancer
Dec 4, 2013
PDF 20.1 KB Add to Briefcase
View Summary Myriad Genetics Announces Second HRD Collaboration
Nov 20, 2013
PDF 15.8 KB Add to Briefcase
View Summary Myriad Genetics Launches myPath(TM) Melanoma Diagnostic Test
Nov 12, 2013
PDF 16.7 KB Add to Briefcase
View Summary Myriad Genetics to Present at the 2013 Credit Suisse Annual Healthcare Conference
Nov 8, 2013
PDF 11.7 KB Add to Briefcase
View Summary Myriad Genetics Reports Financial Results for First Quarter of Fiscal Year 2014
Nov 5, 2013
PDF 26.1 KB Add to Briefcase
Showing 21-40 of 307 Page: 1 2 3 4 5 6 ... 16  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Stock Quote (NASDAQ:MYGN)

Price:
37.02
Change:
- 0.33
Open:
37.26
Previous Close:
37.35
Day High:
37.70
Day Low:
36.80
52 Week High:
42.50
52 Week Low:
20.02
Volume:
442,100
4:00 PM ET on Jul 25, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Investor Contact

Scott Gleason
(801) 584-1143
sgleason@myriad.com

Media Contact

Ron Rogers
Corporate Communications and Media Relations
(801) 584-3065
rrogers@myriad.com